Charles Cotropia - Enzolytics Pres CEO
| ENZC Stock | USD 0.0009 0.0001 10.00% |
Insider
Charles Cotropia is Pres CEO of Enzolytics
| Phone | 972 292 9414 |
| Web | https://enzolytics.com |
Enzolytics Management Efficiency
The company has return on total asset (ROA) of (7.0471) % which means that it has lost $7.0471 on every $100 spent on assets. This is way below average. Enzolytics' management efficiency ratios could be used to measure how well Enzolytics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel Calkins | Verastem | 36 | |
| Valerie MD | Elevation Oncology | 46 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Erin Cox | Verastem | N/A | |
| Sean Flynn | Verastem | 50 | |
| BPHARM RPh | Verastem | 63 | |
| Mba MBA | Verastem | 70 | |
| Piyush Gupta | Verastem | N/A | |
| Jonathan Pachter | Verastem | 66 | |
| Stephen JD | Geron | 74 | |
| David Dornan | Elevation Oncology | 46 | |
| Robert Weinberg | Verastem | N/A | |
| Wolfgang MD | Rigel Pharmaceuticals | 58 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Michelle MD | Verastem | 48 | |
| Christian Mueller | Immutep Ltd ADR | N/A | |
Management Performance
| Return On Asset | -7.05 |
Enzolytics Leadership Team
Elected by the shareholders, the Enzolytics' board of directors comprises two types of representatives: Enzolytics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzolytics. The board's role is to monitor Enzolytics' management team and ensure that shareholders' interests are well served. Enzolytics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzolytics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gaurav MD, COO Director | ||
| Joseph MD, Chief Director | ||
| Harry Zhabilov, Chairman of the Board, CEO | ||
| Charles Cotropia, Pres CEO |
Enzolytics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Enzolytics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -7.05 | |||
| Operating Margin | (19.24) % | |||
| Current Valuation | 71.57 M | |||
| Shares Outstanding | 2.44 B | |||
| Price To Sales | 2,083 X | |||
| Revenue | 190 K | |||
| Gross Profit | 52.81 K | |||
| EBITDA | (886.77 K) | |||
| Net Income | (57.28 K) | |||
| Cash And Equivalents | 5.76 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Enzolytics Pink Sheet
Enzolytics financial ratios help investors to determine whether Enzolytics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Enzolytics with respect to the benefits of owning Enzolytics security.